Inicio › Leucemia mielógena aguda › Pensilvania › Philadelphia
Ensayos clínicos de Leucemia mielógena aguda en Philadelphia, PA
34 estudios para Leucemia mielógena aguda buscan participantes en centros de Philadelphia y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
ReclutandoFase 2
- Thomas Jefferson University Hospital, Philadelphia
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ReclutandoFase 2
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
- Thomas Jefferson University Hospital, Philadelphia
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
ReclutandoFase 1
- Children's Hospital of Philadelphia, Philadelphia
Assessment of Geriatric Evaluations Impact on New AML Guidance
ReclutandoEstudio observacional
- Abramson Cancer Center at University of Pennsylvania, Philadelphia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
- Reading Hospital McGlinn Cancer Institute at Phoenixville, Phoenixville · A 22 mi de distancia
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
ReclutandoEstudio observacional
- Children's Hospital of Philadelphia, Philadelphia
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
ReclutandoFase 3
- Thomas Jefferson University, Philadelphia
- Fox Chase Cancer Center, Philadelphia
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
ReclutandoFase 2
- Thomas Jefferson University Hospital, Philadelphia
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
ReclutandoFase 2
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
- Thomas Jefferson University Hospital, Philadelphia
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
ReclutandoFase 2
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
ReclutandoFase 3
- Children's Hospital of Philadelphia, Philadelphia
- Saint Christopher's Hospital for Children, Philadelphia
- Alfred I duPont Hospital for Children, Wilmington · A 25 mi de distancia
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
ReclutandoFase 1/2
- University of Pennsylvania, Philadelphia
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
ReclutandoFase 1
- UPENN Perelman Center for Advanced Medicine, Philadelphia
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
ReclutandoFase 3
- Children's Hospital of Philadelphia, Philadelphia
- Alfred I duPont Hospital for Children, Wilmington · A 25 mi de distancia
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
ReclutandoFase 1/2
- Children's Hospital of Philadelphia, Philadelphia
- Saint Christopher's Hospital for Children, Philadelphia
- Alfred I duPont Hospital for Children, Wilmington · A 25 mi de distancia
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
ReclutandoFase 3
- Children's Hospital of Philadelphia, Philadelphia
- Nemours Alfred I. Dupont Hospital for Children, Wilmington · A 25 mi de distancia
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
ReclutandoFase 3
- University of Pennsylvania, Philadelphia
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
ReclutandoFase 2/3
- University of Pennsylvania, Philadelphia
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
ReclutandoFase 1
- Children's Hospital of Philadelphia, Philadelphia
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
ReclutandoFase 2
- Penn Medicine Abramson Cancer Center, Philadelphia
CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML
ReclutandoFase 1
- University of Pennsylvania, Philadelphia
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
Reclutando
- Children's Hospital of Philadelphia, Philadelphia
CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia
ReclutandoFase 1
- Children's Hospital of Philadelphia, Philadelphia
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
ReclutandoEstudio observacional
- Children's Hospital of Philadelphia, Philadelphia
- Nemours - Alfred I. duPont Hospital for Children, Brandywine · A 21 mi de distancia
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
ReclutandoFase 1/2
- Penn Medicine - Abramson Cancer Center Perelman, Philadelphia
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
ReclutandoFase 1
- University of Pennsylvania, Philadelphia
Massage Impact on Sleep in Pediatric Oncology
Reclutando
- Children's Hospital of Philadelphia, Philadelphia
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
ReclutandoFase 1/2
- Sidney Kimmel Comprehensive Cancer Center, Philadelphia
Phase IB/II of CPX-351 for Relapse Prevention in AML
ReclutandoFase 1/2
- University of Pennsylvania, Philadelphia
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
ReclutandoFase 1
- Thomas Jefferson University Hospital, Philadelphia
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
ReclutandoFase 1
- Hospital of the University of Pennsylvania, Philadelphia
Tazemetostat and Palbociclib With CPX-351for R/R AML
ReclutandoFase 1
- Thomas Jefferson University Hospital, Philadelphia
Home Blood Transfusions
Reclutando
- Thomas Jefferson University Hospital, Philadelphia
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
ReclutandoSe aceptan voluntarios sanos
- University of Pennsylvania, Philadelphia
Más información sobre Leucemia mielógena aguda en MedlinePlus
Ensayos de Leucemia mielógena aguda en otras ciudades
- Houston, TX85 estudios
- New York City, NY51 estudios
- Boston, MA44 estudios
- Seattle, WA41 estudios
- Baldwin Park, CA40 estudios
- Columbus, OH35 estudios
- Durham, NC33 estudios
- Atlanta, GA31 estudios
- Tampa, FL29 estudios
- Chicago, IL26 estudios
- Portland, OR25 estudios
- Washington, DC24 estudios
Otros estudios en Philadelphia
- Cáncer (todos los tipos)59 estudios
- Cáncer de seno56 estudios
- Cáncer de pulmón de células no pequeñas51 estudios
- Cáncer metastásico46 estudios
- Cáncer de próstata44 estudios
- Cáncer del colon y del recto44 estudios
- Cáncer de ovario44 estudios
- Cáncer de pulmón36 estudios
- Fallo cardíaco31 estudios
- Cáncer de endometrio28 estudios
- Depresión26 estudios
- Cáncer de páncreas26 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.